ABBVIE
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
- Conditions
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 90
- Registration Number
- NCT05609630
- Locations
- 🇯🇵
Institute of Science Tokyo Hospital /ID# 251505, Bunkyo-ku, Tokyo, Japan
🇸🇪Queen Silvia Children's Hosp /ID# 251318, Gothenburg, Vastra Gotalands Lan, Sweden
🇺🇸New York Medical College /ID# 253437, Valhalla, New York, United States
Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adult Participants With Ankylosing Spondylitis in the Real-World Japan
- Conditions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT05609643
- Locations
- 🇯🇵
Yagi Hospital /ID# 251078, Fukuoka-shi, Fukuoka, Japan
🇯🇵Kunou Orthopedic Clinic /ID# 252168, Kitakyushu-shi, Fukuoka, Japan
🇯🇵Kobe Kaisei Hospital /ID# 251073, Kobe-shi, Hyogo, Japan
A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique
- Conditions
- Interventions
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- AbbVie
- Registration Number
- NCT05606757
- Locations
- 🇺🇸
Atrium Health Carolinas Medical Center /ID# 247711, Charlotte, North Carolina, United States
🇺🇸NYU Langone Hospital - Long Island /ID# 251280, Mineola, New York, United States
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 926
- Registration Number
- NCT05601882
- Locations
- 🇺🇸
Florida International Rsrch cr /ID# 249667, Miami, Florida, United States
🇨🇳The second affiliated hospital of Zhejiang University school of medicine /ID# 249655, Hangzhou, Zhejiang, China
🇩🇪Universitaetsklinikum Schleswig-Holstein Campus Luebeck /ID# 249560, Lübeck, Schleswig-Holstein, Germany
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 350
- Registration Number
- NCT05599984
- Locations
- 🇩🇪
Klinikum der Universität München - Campus Innenstadt /ID# 259412, Munich, Bayern, Germany
🇺🇸Banner MD Anderson Cancer Ctr /ID# 260129, Gilbert, Arizona, United States
🇺🇸City Of Hope Comprehensive Cancer Center /ID# 271295, Duarte, California, United States
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia
- Conditions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 70
- Registration Number
- NCT05587049
- Locations
- 🇨🇴
Sociedad de Oncologia y Hematologia del Cesar /ID# 248615, Valledupar, Cesar, Colombia
🇨🇴Coorp Hosp Juan Ciudad Sede Hospital Universitario Mayor Mederi /ID# 248570, Bogota DC, Cundinamarca, Colombia
🇨🇴Fundacion Valle Del Lili /ID# 248294, Cali, Valle Del Cauca, Colombia
Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 40
- Registration Number
- NCT05570006
- Locations
- 🇺🇸
Gastro SB /ID# 249271, Chula Vista, California, United States
🇺🇸Ctr for Advanced Gastroenterol /ID# 249226, Maitland, Florida, United States
🇺🇸Atlantic Medical Research /ID# 249213, Margate, Florida, United States
Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.
- Conditions
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 198
- Registration Number
- NCT05567029
- Locations
- 🇺🇸
Anaheim Clinical Trials LLC /ID# 250098, Anaheim, California, United States
🇺🇸Bio-Kinetic Clinical Applications, LLC /ID# 250181, Springfield, Missouri, United States
🇺🇸PPD Clinical Research Unit - Austin /ID# 250672, Austin, Texas, United States
Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 40
- Registration Number
- NCT05556226
- Locations
- 🇺🇸
Acpru /Id# 250429, Grayslake, Illinois, United States
🇺🇸PPD Clinical Research Unit -Las Vegas /ID# 250650, Las Vegas, Nevada, United States
A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom
- Conditions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT05555979
- Locations
- 🇬🇧
Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 252720, Norwich, Norfolk, United Kingdom
🇬🇧Oxford University Hospitals NHS Foundation Trust /ID# 252715, Oxford, Oxfordshire, United Kingdom
🇬🇧Barts Health NHS Trust /ID# 252717, London, London, City Of, United Kingdom